We are launching our new website!
Friends, Senzime has a new fresh look on the web - go visit and learn about our breakthrough technology.
Now it is finally here; the new website for Senzime AB -
Welcome to our new website. Now we have changed the look and improved our website. It differs in appearance from our previous site and we have improved both the content and layout.
We have given our website a new face that follows our visual identity and that hopefully will give visitors an easier overview of all the information we want to convey.
For further information, please contact:
Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com
TO THE EDITORS
About Senzime
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com